HLA-B44 (C57BL/6)

Random Transgenic

HLA-B44 (C57BL/6)
This model is produced upon order and takes a minimum of 6 weeks to deliver.

This model is impacted by a newly discovered spontaneous mutation in the Thyroglobulin (Tg) gene. It will be removed over time through selective breeding. See the Fact Sheet for more information.

C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 8911-F
  • 8911-M
  • Carries a transgene consisting of fragments of the human HLA-B*4002 gene and mouse H2-Kb gene which encodes a chimeric class I molecule consisting of the human HLA-B44 leader, α1 and α2 domains ligated to the murine α3, transmembrane and cytoplasmic H2-Kb domains.
  • Expresses the chimeric HLA-B44 class I molecule on the surface of T and B cells.
  • Represents the human HLA-B44 supertype. The B*40:02 allele is a member of the B44-binding supertype, which encompasses a group of HLA B alleles sharing a binding specificity for peptides with E in position 2 and aliphatic/hydrophobic residues at the C-terminus. B61 is a serological designation. The B61 serological antigen is present on several B*40 subtypes (including B*40:02). With one possible exception, all alleles with the B61 serological antigen are expected to share the same main binding specificity as B*40:02, and hence have been defined as members of the B44 binding supertype.
  • Useful for infectious disease research, vaccine development and testing, safety and immunogenicity testing as well as research directed towards oncology and autoimmune disorders and syngeneic tumor studies utilizing C57BL/6-derived tumors.
  • Permits identification of epitopes restricted to the HLA-B44 supertype.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:



The HLA-B44 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the genomic clone of the human HLA-B*4002 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains, all under the control of the murine H2-Kb promoter. This transgene was microinjected into C57BL/6 zygotes. The resultant mice from Founder Line B44.01 were on an inbred C57BL/6 background. The line was maintained by breeding hemizygotes to wild type C57BL/6NTac mice for 4 generations. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived by breeding C57BL/6NTac wild type females to hemizygous males and then was intracrossed to homozygosity. The colony is maintained through breeding of homozygous males to homozygous females. SNP profiles indicate that the strain is currently at 100% (NE10) on the C57BL/6NTac genetic background. In the production colony, wild type C57BL/6NTac females are bred to homozygous males on the C57BL/6NTac background to produce hemizygous pups on the C57BL/6NTac background. In addition, another production colony is breeding BALB/cAnNTac females with homozygous males on the C57BL/6NTAC background to product hemizygous CB6F1 pups, which are sold under model #9664.





Initial Publication:

Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L. (2008) Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 82(1):435-50.

This publication does not describe the HLA-B44 strain, but the HLA-B44 strain was generated in a similar manner to that of the other transgenic HLA mouse strains described in the publication and may be used for similar types of experiments.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.
This model is produced upon demand and will not always have an active health report.

Welcome! Tell us a little about yourself